Malignancy risk and mortality after lung transplantation: A single-institution experience over 31 years.
Journal: JHLT open
Year: March 27, 2025
Oncologist
5
No OPD information available
Melanoma
Melanoma of the Eye
Uveal Melanoma
Lung Metastases
Merkel Cell Carcinoma
Mosaicism
Neuroendocrine Tumor
Retinal Artery Occlusion
Mark J. Shackleton is a male medical professional who specializes in treating various conditions such as melanoma, melanoma of the eye, uveal melanoma, lung metastases, Merkel cell carcinoma, mosaicism, neuroendocrine tumor, and retinal artery occlusion.
Mark J. Shackleton helps patients by providing specialized care for these conditions. He uses his expertise and skills to diagnose and treat patients effectively. Patients trust him because he communicates clearly and compassionately, making sure they understand their treatment options and feel supported throughout their medical journey.
To stay updated with the latest medical knowledge and research, Mark J. Shackleton regularly attends conferences, reads medical journals, and collaborates with other healthcare professionals. This dedication to learning ensures that he can offer the most advanced and effective treatments to his patients.
Mark J. Shackleton works closely with colleagues and other medical professionals to provide comprehensive care to patients. He values teamwork and believes that by working together, they can achieve the best outcomes for their patients.
Through his work, Mark J. Shackleton has made a positive impact on many patients' lives by improving their health outcomes and quality of life. His dedication to his patients and his commitment to providing excellent care have earned him the trust and gratitude of those he treats.
One of Mark J. Shackleton's notable publications is "Malignancy risk and mortality after lung transplantation: A single-institution experience over 31 years," published in JHLT open on March 27, 2025. He is also involved in a clinical trial titled "A Randomised, Placebo-controlled, Phase II Trial of Adjuvant Avelumab in Patients With Stage I-III Merkel Cell Carcinoma," which is currently active but not recruiting participants.
In summary, Mark J. Shackleton is a dedicated and skilled medical professional who goes above and beyond to provide exceptional care to his patients and contribute to advancements in the field of medicine.
Journal: JHLT open
Year: March 27, 2025
Enrollment Status: Active not recruiting
Published: April 03, 2025
Intervention Type: Drug
Study Drug: Avelumab
Study Phase: Phase 2
Mark J. Shackleton is an amazing Oncologist. He explained everything clearly and made me feel at ease throughout my treatment. Highly recommend!
Dr. Shackleton is a compassionate and knowledgeable Oncologist. He truly cares about his patients and goes above and beyond to provide the best care possible.
I am so grateful for the care I received from Mark J. Shackleton. He is an exceptional Oncologist who is dedicated to helping his patients every step of the way.
Dr. Shackleton is a top-notch Oncologist. His expertise and kindness made a difficult time much more manageable. I couldn't have asked for a better doctor.
Mark J. Shackleton is an outstanding Oncologist. He took the time to listen to my concerns and provided personalized care that made a big difference in my treatment.
I highly recommend Dr. Shackleton as an Oncologist. He is not only skilled in his field but also has a warm and comforting approach that puts patients at ease.
Dr. Shackleton is a fantastic Oncologist. His expertise and genuine care for his patients shine through in every interaction. I am so thankful for his support.
Mark J. Shackleton is an exceptional Oncologist who truly goes above and beyond for his patients. I am so grateful for his expertise and compassion.